Pub Date : 2023-12-01DOI: 10.1007/s12254-023-00925-x
Aysegül Ilhan-Mutlu
{"title":"HER2 in focus—gastric cancer","authors":"Aysegül Ilhan-Mutlu","doi":"10.1007/s12254-023-00925-x","DOIUrl":"https://doi.org/10.1007/s12254-023-00925-x","url":null,"abstract":"","PeriodicalId":18379,"journal":{"name":"memo - Magazine of European Medical Oncology","volume":"133 1","pages":"217 - 217"},"PeriodicalIF":0.6,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138621568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-01DOI: 10.1007/s12254-023-00930-0
Gabriel Rinnerthaler
{"title":"ASCO 2023—partnering with patients: the cornerstone of cancer care and research","authors":"Gabriel Rinnerthaler","doi":"10.1007/s12254-023-00930-0","DOIUrl":"https://doi.org/10.1007/s12254-023-00930-0","url":null,"abstract":"","PeriodicalId":18379,"journal":{"name":"memo - Magazine of European Medical Oncology","volume":"117 42","pages":"215 - 216"},"PeriodicalIF":0.6,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138608171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-01DOI: 10.1007/s12254-023-00940-y
{"title":"A CONGRESS DIGEST ON RADIOLABELED THERANOSTICS FOR SOLID TUMORS. Report from the 36th Annual Congress of the European Association of Nuclear Medicine (EANM), September 9th – 13th, 2023, Vienna","authors":"","doi":"10.1007/s12254-023-00940-y","DOIUrl":"https://doi.org/10.1007/s12254-023-00940-y","url":null,"abstract":"","PeriodicalId":18379,"journal":{"name":"memo - Magazine of European Medical Oncology","volume":" 7","pages":"143 - 161"},"PeriodicalIF":0.6,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138610042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-01DOI: 10.1007/s12254-023-00923-z
S. Shariat
{"title":"Prostate cancer special—part 1","authors":"S. Shariat","doi":"10.1007/s12254-023-00923-z","DOIUrl":"https://doi.org/10.1007/s12254-023-00923-z","url":null,"abstract":"","PeriodicalId":18379,"journal":{"name":"memo - Magazine of European Medical Oncology","volume":" 34","pages":"218 - 219"},"PeriodicalIF":0.6,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138618305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-01DOI: 10.1007/s12254-023-00926-w
Christoph Minichsdorfer, PhD
{"title":"Supportive management","authors":"Christoph Minichsdorfer, PhD","doi":"10.1007/s12254-023-00926-w","DOIUrl":"https://doi.org/10.1007/s12254-023-00926-w","url":null,"abstract":"","PeriodicalId":18379,"journal":{"name":"memo - Magazine of European Medical Oncology","volume":"102 3","pages":"220 - 221"},"PeriodicalIF":0.6,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138609144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-28DOI: 10.1007/s12254-023-00939-5
MD Alex A. Adjei, MD Luana Calabró, Maria Rosario, MD Garcia Campelo, MD Federico Cappuzzo, MD Michaël Duruisseaux, MD Wolfgang Hilbe, MD Maximilian Hochmair, MD Maarten Lambrecht, MD Herbert H F Loong, MD Stephen V. Liu, MD Filippo de Marinis, MD Frcpc Barbara Melosky, PhD Luis Montuenga, MD Nir Peled, MD Robert Pirker, MD Jordi Remon, MD Lung Clinic Grosshansdorf Martin Reck, MD Lung Cancer Group Cologne Matthias Scheffler, PhD Frcp Riyaz Shah, PhD Yu Shyr, MB Ross Soo, MD Alexander Spira, MD Masahiro Tsuboi, M. H. William N. William, Beneficência Portuguesa de, São Paulo, Brazil Yi-Long, MD Facs Wu, PhD Anna Fenzl, MD Navneet Singh, MD. Judith Moser
{"title":"A GLOBAL CONGRESS DIGEST ON LUNG CANCER. Report from the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer, September 9th-12th , hybrid congress","authors":"MD Alex A. Adjei, MD Luana Calabró, Maria Rosario, MD Garcia Campelo, MD Federico Cappuzzo, MD Michaël Duruisseaux, MD Wolfgang Hilbe, MD Maximilian Hochmair, MD Maarten Lambrecht, MD Herbert H F Loong, MD Stephen V. Liu, MD Filippo de Marinis, MD Frcpc Barbara Melosky, PhD Luis Montuenga, MD Nir Peled, MD Robert Pirker, MD Jordi Remon, MD Lung Clinic Grosshansdorf Martin Reck, MD Lung Cancer Group Cologne Matthias Scheffler, PhD Frcp Riyaz Shah, PhD Yu Shyr, MB Ross Soo, MD Alexander Spira, MD Masahiro Tsuboi, M. H. William N. William, Beneficência Portuguesa de, São Paulo, Brazil Yi-Long, MD Facs Wu, PhD Anna Fenzl, MD Navneet Singh, MD. Judith Moser","doi":"10.1007/s12254-023-00939-5","DOIUrl":"https://doi.org/10.1007/s12254-023-00939-5","url":null,"abstract":"","PeriodicalId":18379,"journal":{"name":"memo - Magazine of European Medical Oncology","volume":"110 1","pages":"125 - 142"},"PeriodicalIF":0.6,"publicationDate":"2023-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139219349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-20DOI: 10.1007/s12254-023-00933-x
Yu Fu, Long Su, Yuying Li, Yehui Tan
{"title":"Decitabine combined with low-dose cytarabine, aclarubicin and rhG-CSF regimen may be a potential alternative for relapsed/refractory acute myeloid leukemia: A single-center study","authors":"Yu Fu, Long Su, Yuying Li, Yehui Tan","doi":"10.1007/s12254-023-00933-x","DOIUrl":"https://doi.org/10.1007/s12254-023-00933-x","url":null,"abstract":"","PeriodicalId":18379,"journal":{"name":"memo - Magazine of European Medical Oncology","volume":"16 5","pages":""},"PeriodicalIF":0.6,"publicationDate":"2023-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139255486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-13DOI: 10.1007/s12254-023-00931-z
Patrick Reimann, Thomas Winder
{"title":"Essential news from ASCO 2023 in primary resectable and advanced or metastatic pancreatic cancer","authors":"Patrick Reimann, Thomas Winder","doi":"10.1007/s12254-023-00931-z","DOIUrl":"https://doi.org/10.1007/s12254-023-00931-z","url":null,"abstract":"","PeriodicalId":18379,"journal":{"name":"memo - Magazine of European Medical Oncology","volume":"66 39","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136281569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-10DOI: 10.1007/s12254-023-00932-y
Nicolai A. Huebner, Stephan Korn, Pawel Rajwa, Shahrokh F. Shariat
Summary Focal therapy is a treatment option for clinically localized prostate cancer, finding increased use in recent years. It is generally associated with very good functional outcome regarding pad-free continence and preservation of erections. Oncologic outcomes are controversial, especially depending on the ideal endpoint. Both the presence of clinically significant prostate cancer (csPCA) on biopsy and the absence of any whole-gland or systemic treatment as “failure-free survival” (FFS) have been used. While salvage whole-gland and systemic therapy is rare, a substantial number of patients will have csPCA on follow-up biopsies after focal therapy, either in-field or out of field. Generally, patients selected for focal therapy are considered intermediate-risk, although some patients with high-risk features have been included into focal therapy studies. With the data currently available focal therapy presents a good treatment option for patients with feasible intermediate-risk prostate cancer, interested in functional outcome, after proper counseling on the higher recurrence rate, and the need for surveillance biopsies during follow-up.
{"title":"Focal therapy in intermediate- and high-risk prostate cancer","authors":"Nicolai A. Huebner, Stephan Korn, Pawel Rajwa, Shahrokh F. Shariat","doi":"10.1007/s12254-023-00932-y","DOIUrl":"https://doi.org/10.1007/s12254-023-00932-y","url":null,"abstract":"Summary Focal therapy is a treatment option for clinically localized prostate cancer, finding increased use in recent years. It is generally associated with very good functional outcome regarding pad-free continence and preservation of erections. Oncologic outcomes are controversial, especially depending on the ideal endpoint. Both the presence of clinically significant prostate cancer (csPCA) on biopsy and the absence of any whole-gland or systemic treatment as “failure-free survival” (FFS) have been used. While salvage whole-gland and systemic therapy is rare, a substantial number of patients will have csPCA on follow-up biopsies after focal therapy, either in-field or out of field. Generally, patients selected for focal therapy are considered intermediate-risk, although some patients with high-risk features have been included into focal therapy studies. With the data currently available focal therapy presents a good treatment option for patients with feasible intermediate-risk prostate cancer, interested in functional outcome, after proper counseling on the higher recurrence rate, and the need for surveillance biopsies during follow-up.","PeriodicalId":18379,"journal":{"name":"memo - Magazine of European Medical Oncology","volume":"113 52","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135137266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：